Skip to main content
Premium Trial:

Request an Annual Quote

Cezanne to Use Lumiphore Reagents in Dx Tests

NEW YORK (GenomeWeb News) – Brahms subsidiary Cezanne will incorporate technology from Lumiphore in its diagnostic tests under two new agreements, Richmond, Calif.-based Lumiphore said today.

Brahms and Cezanne will use the Lumi4-Tb technology in development of current and future diagnostic tests under a non-exclusive agreement. In addition, Cezanne acquired exclusive rights to use the technology in diagnostic tests for Down's Syndrome, including tests for Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism, the company said.

The Lumiphore technology uses fluorescent-metal lanthanide detection reagents that have long emission lifetimes and offer high stability, multiplexing, and high signal-to-noise ratio, the firms said. Brahms' Kryptor analysis systems use time-resolved amplified cryptate emission technology for measuring molecular interactions.

Using the Lumi4-Tb technology "will not only increase the sensitivity of Brahms diagnostic tests, but will also allow the development of multiplexed assays," Cezanne CEO Emmanuel Bois said in a statement.

Financial terms of the agreement were not released.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.